Question to the Department of Health and Social Care:

To ask Her Majesty’s Government what assessment they have made of the potential savings to the budgets of Clinical Commissioning Groups from the use of the drug bevacizumab in the treatment of age-related macular degeneration instead of ranibizumab.

No assessment of the potential savings to clinical commissioning group budgets has been made as there are two other effective licensed treatments for wet age-related macular degeneration recommended by the National Institute for Health and Care Excellence.